

Note: This document has been translated from the Japanese original for reference purposes only, and is not intended to solicit an investment in the Company or similar activity. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from the translation.



August 1, 2025  
Fuji Pharma Co., Ltd.

## **Notice Concerning Completion Acquisition and Cancellation of the 1st Series of Stock Acquisition Rights with Exercise Price Revision Clause**

Fuji Pharma Co., Ltd. hereby announces that, as previously disclosed in the “Notice Concerning Acquisition and Cancellation of the 1st Series of Stock Acquisition Rights with Exercise Price Revision Clause” dated July 17, 2025, the Company has completed the acquisition and cancellation of all remaining stock acquisition rights of the 1st Series issued on August 5, 2024, as outlined below.

### **1. Details of Acquisition and cancellation**

(1) Name of stock acquisition rights to be acquired and cancelled	Fuji Pharma Co., Ltd. 1st Series of Stock Acquisition Rights
(2) Number of stock acquisition rights acquired and cancelled	23,627units
(3) Acquisition and cancellation date	August 1, 2025
(4) Acquisition cost	6,379,290 yen (270 yen per one unit)
(5) Number of stock acquisition rights remaining after cancellation	0 units

### **2. Future outlook**

The acquisition and cancellation of the 1st Series of Stock Acquisition Rights will have a negligible impact on the Company’s business results for the current fiscal year.

### **For further information, contact**

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

[fsk\\_ir@fujipharma.jp](mailto:fsk_ir@fujipharma.jp)